Logo image of DAWN

DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DAWN - US23954D1090 - Common Stock

8.295 USD
-0.13 (-1.6%)
Last: 12/3/2025, 3:24:07 PM
Fundamental Rating

4

DAWN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. DAWN has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, DAWN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DAWN has reported negative net income.
In the past year DAWN has reported a negative cash flow from operations.
DAWN had negative earnings in each of the past 5 years.
In the past 5 years DAWN always reported negative operating cash flow.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of DAWN (-29.54%) is better than 67.60% of its industry peers.
The Return On Equity of DAWN (-33.66%) is better than 74.53% of its industry peers.
Industry RankSector Rank
ROA -29.54%
ROE -33.66%
ROIC N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

DAWN has a Gross Margin of 89.44%. This is amongst the best in the industry. DAWN outperforms 91.20% of its industry peers.
The Profit Margin and Operating Margin are not available for DAWN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DAWN has more shares outstanding
DAWN has more shares outstanding than it did 5 years ago.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 6.72 indicates that DAWN is not in any danger for bankruptcy at the moment.
DAWN's Altman-Z score of 6.72 is fine compared to the rest of the industry. DAWN outperforms 77.53% of its industry peers.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.72
ROIC/WACCN/A
WACC8.73%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

DAWN has a Current Ratio of 8.68. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.68, DAWN is doing good in the industry, outperforming 77.15% of the companies in the same industry.
A Quick Ratio of 8.55 indicates that DAWN has no problem at all paying its short term obligations.
DAWN has a better Quick ratio (8.55) than 76.59% of its industry peers.
Industry RankSector Rank
Current Ratio 8.68
Quick Ratio 8.55
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.42% over the past year.
The Revenue has grown by 31.11% in the past year. This is a very strong growth!
EPS 1Y (TTM)17.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.65%
Revenue 1Y (TTM)31.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%98.28%

3.2 Future

The Earnings Per Share is expected to grow by 24.77% on average over the next years. This is a very strong growth
DAWN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.57% yearly.
EPS Next Y30.15%
EPS Next 2Y24.39%
EPS Next 3Y25.97%
EPS Next 5Y24.77%
Revenue Next Year18.47%
Revenue Next 2Y32.54%
Revenue Next 3Y35.16%
Revenue Next 5Y36.57%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DAWN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as DAWN's earnings are expected to grow with 25.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.39%
EPS Next 3Y25.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DAWN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (12/3/2025, 3:24:07 PM)

8.295

-0.13 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-02 2026-02-02/amc
Inst Owners85.34%
Inst Owner Change-2.44%
Ins Owners2.32%
Ins Owner Change0.29%
Market Cap851.73M
Revenue(TTM)133.67M
Net Income(TTM)-151.76M
Analysts82.5
Price Target22.7 (173.66%)
Short Float %10.7%
Short Ratio4.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.36%
Min EPS beat(2)20.33%
Max EPS beat(2)36.38%
EPS beat(4)3
Avg EPS beat(4)1.46%
Min EPS beat(4)-73.33%
Max EPS beat(4)36.38%
EPS beat(8)5
Avg EPS beat(8)12.11%
EPS beat(12)9
Avg EPS beat(12)9.7%
EPS beat(16)11
Avg EPS beat(16)4.84%
Revenue beat(2)1
Avg Revenue beat(2)-1.85%
Min Revenue beat(2)-5.83%
Max Revenue beat(2)2.13%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-5.83%
Max Revenue beat(4)3.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.3%
PT rev (3m)-3.26%
EPS NQ rev (1m)30.36%
EPS NQ rev (3m)33.15%
EPS NY rev (1m)0.41%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)4.08%
Revenue NQ rev (3m)5.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.37
P/FCF N/A
P/OCF N/A
P/B 1.89
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS1.3
BVpS4.39
TBVpS4.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.54%
ROE -33.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.44%
FCFM N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.44%
Cap/Sales 3.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.68
Quick Ratio 8.55
Altman-Z 6.72
F-Score3
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)635.28%
Cap/Depr(5y)471.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.65%
EPS Next Y30.15%
EPS Next 2Y24.39%
EPS Next 3Y25.97%
EPS Next 5Y24.77%
Revenue 1Y (TTM)31.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%98.28%
Revenue Next Year18.47%
Revenue Next 2Y32.54%
Revenue Next 3Y35.16%
Revenue Next 5Y36.57%
EBIT growth 1Y21.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.31%
EBIT Next 3Y17.93%
EBIT Next 5YN/A
FCF growth 1Y11.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.04%
OCF growth 3YN/A
OCF growth 5YN/A

DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ

What is the fundamental rating for DAWN stock?

ChartMill assigns a fundamental rating of 4 / 10 to DAWN.


Can you provide the valuation status for DAY ONE BIOPHARMACEUTICALS I?

ChartMill assigns a valuation rating of 1 / 10 to DAY ONE BIOPHARMACEUTICALS I (DAWN). This can be considered as Overvalued.


What is the profitability of DAWN stock?

DAY ONE BIOPHARMACEUTICALS I (DAWN) has a profitability rating of 2 / 10.


What is the financial health of DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?

The financial health rating of DAY ONE BIOPHARMACEUTICALS I (DAWN) is 8 / 10.